Drug
Fab122
Fab122: highest development phase Phase 3, developed by Ferrer. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ferrer
Trials
| Drug | Phase | Indication |
|---|---|---|
| FAB122 NCT05178810 | Phase 3 | Amyotrophic Lateral Sclerosis |
| FAB122 NCT05866926 | Phase 3 | Amyotrophic Lateral Sclerosis |
Latest
No recent events.
Follow Fab122 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.